• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

惰性B细胞恶性肿瘤向侵袭性B细胞恶性肿瘤转变的分子机制

Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.

作者信息

Maher Nawar, Mouhssine Samir, Matti Bassam Francis, Alwan Alaa Fadhil, Gaidano Gianluca

机构信息

Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, 28100 Novara, Italy.

Department of Hematology and Bone Marrow Transplant, Hematology and Bone Marrow Transplant Center, Medical City, Baghdad 00964, Iraq.

出版信息

Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907.

DOI:10.3390/cancers17050907
PMID:40075754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11899122/
Abstract

Histological transformation (HT) into aggressive lymphoma is a turning point in a significant fraction of patients affected by indolent lymphoproliferative neoplasms, namely, chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), marginal zone lymphomas (MZLs), and lymphoplasmacytic lymphoma (LPL) [...].

摘要

向侵袭性淋巴瘤的组织学转化（HT）是相当一部分惰性淋巴细胞增殖性肿瘤患者的转折点，这些肿瘤包括慢性淋巴细胞白血病（CLL）、滤泡性淋巴瘤（FL）、边缘区淋巴瘤（MZL）和淋巴浆细胞淋巴瘤（LPL）[...]。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11899122/b0c43910aa6a/cancers-17-00907-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11899122/9e41e5294758/cancers-17-00907-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11899122/b0c43910aa6a/cancers-17-00907-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11899122/9e41e5294758/cancers-17-00907-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/38de/11899122/b0c43910aa6a/cancers-17-00907-g002.jpg

相似文献

1
Molecular Mechanisms in the Transformation from Indolent to Aggressive B Cell Malignancies.惰性B细胞恶性肿瘤向侵袭性B细胞恶性肿瘤转变的分子机制
Cancers (Basel). 2025 Mar 6;17(5):907. doi: 10.3390/cancers17050907.
2
Burkitt lymphoma in patients with chronic lymphocytic leukemia and other indolent B-cell lymphoid malignancies.慢性淋巴细胞白血病及其他惰性B细胞淋巴样恶性肿瘤患者中的伯基特淋巴瘤。
Leuk Lymphoma. 2025 Mar 25:1-13. doi: 10.1080/10428194.2025.2475337.
3
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.利妥昔单抗：用于非霍奇金淋巴瘤和慢性淋巴细胞白血病的综述
Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005.
4
Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.计算机断层扫描纹理分析在慢性淋巴细胞白血病和里希特综合征弥漫性大 B 细胞淋巴瘤中的鉴别诊断。
Eur Radiol. 2019 Dec;29(12):6911-6921. doi: 10.1007/s00330-019-06291-9. Epub 2019 Jun 24.
5
The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies.MYC 在“惰性”B 细胞恶性肿瘤的转化和侵袭中的作用。
Leuk Lymphoma. 2020 Mar;61(3):510-524. doi: 10.1080/10428194.2019.1675877. Epub 2019 Oct 20.
6
Immunohistochemical Expression of Lymphoid Enhancer Binding Factor 1 in CD5-Positive Marginal Zone, Lymphoplasmacytic, and Follicular Lymphomas.CD5 阳性边缘区、淋巴浆细胞性和滤泡性淋巴瘤中淋巴增强结合因子 1 的免疫组织化学表达。
Am J Clin Pathol. 2020 Apr 15;153(5):646-655. doi: 10.1093/ajcp/aqz207.
7
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.苯达莫司汀用于治疗惰性B细胞淋巴瘤患者，包括慢性淋巴细胞白血病。
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD009045. doi: 10.1002/14651858.CD009045.pub2.
8
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.慢性淋巴细胞白血病/小淋巴细胞淋巴瘤与其他惰性淋巴瘤（包括套细胞淋巴瘤）的鉴别诊断。
J Clin Exp Hematop. 2020 Dec 15;60(4):124-129. doi: 10.3960/jslrt.19041. Epub 2020 Apr 3.
9
Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia.儿童群体中的惰性淋巴瘤：滤泡性淋巴瘤、IRF4/MUM1+淋巴瘤、结内边缘区淋巴瘤和慢性淋巴细胞白血病。
Virchows Arch. 2016 Feb;468(2):141-57. doi: 10.1007/s00428-015-1855-z. Epub 2015 Sep 28.
10
Pathology of indolent B-cell neoplasms other than follicular lymphoma.除滤泡性淋巴瘤外的惰性B细胞肿瘤的病理学
J Clin Exp Hematop. 2014;54(1):11-22. doi: 10.3960/jslrt.54.11.

引用本文的文献

1
Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation.慢性淋巴细胞白血病：正在研究的新型治疗靶点
Cancers (Basel). 2025 Jul 10;17(14):2298. doi: 10.3390/cancers17142298.
2
Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.B细胞和T细胞淋巴瘤的液体活检：从实验台到病床旁
Int J Mol Sci. 2025 May 19;26(10):4869. doi: 10.3390/ijms26104869.

本文引用的文献

1
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.细胞周期蛋白依赖性蛋白激酶与生物学和疾病中的细胞周期调控
Signal Transduct Target Ther. 2025 Jan 13;10(1):11. doi: 10.1038/s41392-024-02080-z.
2
Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.免疫球蛋白轻链突变状态可优化IGHV在识别需要早期治疗的慢性淋巴细胞白血病患者中的预后价值。
Leukemia. 2025 Mar;39(3):643-649. doi: 10.1038/s41375-024-02499-x. Epub 2024 Dec 17.
3
Unraveling the Guardian: p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies.
解读守护者：p53在DNA损伤应答及肿瘤治疗策略中的多面角色
Int J Mol Sci. 2024 Dec 1;25(23):12928. doi: 10.3390/ijms252312928.
4
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era.靶向治疗时代慢性淋巴细胞白血病/小淋巴细胞淋巴瘤Richter转化的发生率。
Leukemia. 2025 Feb;39(2):503-507. doi: 10.1038/s41375-024-02492-4. Epub 2024 Dec 10.
5
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial.阿替利珠单抗、维奈托克和奥滨尤妥珠单抗联合治疗Richter 转化弥漫性大 B 细胞淋巴瘤（MOLTO）：一项多中心、单臂、2 期临床试验。
Lancet Oncol. 2024 Oct;25(10):1298-1309. doi: 10.1016/S1470-2045(24)00396-6. Epub 2024 Sep 10.
6
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia.欧洲肿瘤内科学会（ESMO）慢性淋巴细胞白血病一线及复发时新型靶向治疗的临床实践指南临时更新
Ann Oncol. 2024 Sep;35(9):762-768. doi: 10.1016/j.annonc.2024.06.016. Epub 2024 Jul 3.
7
Current Therapeutic Sequencing in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病的当前治疗顺序
Hematol Rep. 2024 Apr 30;16(2):270-282. doi: 10.3390/hematolrep16020027.
8
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.靶向 B 细胞恶性肿瘤中的 BTK：从作用机制到耐药机制。
Int J Mol Sci. 2024 Mar 12;25(6):3234. doi: 10.3390/ijms25063234.
9
A STEP ahead for CAR-T cell therapy of large B cell lymphoma: understanding the molecular determinants of resistance.大B细胞淋巴瘤嵌合抗原受体T细胞（CAR-T）疗法的一大进步：了解耐药性的分子决定因素
Transl Cancer Res. 2023 Nov 30;12(11):2970-2975. doi: 10.21037/tcr-23-1396. Epub 2023 Nov 17.
10
DLBCL arising from indolent lymphomas: How are they different?惰性淋巴瘤衍生的弥漫大 B 细胞淋巴瘤：它们有何不同？
Semin Hematol. 2023 Nov;60(5):277-284. doi: 10.1053/j.seminhematol.2023.11.002. Epub 2023 Nov 23.